Posted by Michael Wonder on 17 Jun 2021
Ontozry scores MHRA authorisation for focal-onset seizures
17 June 2021 - The MHRA has granted Arvelle Therapeutics’ Ontozry a marketing authorisation for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation.
The marketing authorisation covers Ontozry (cenobamate) for use in adult patients with epilepsy who have not been adequately controlled despite treatment with at least two anti-epileptic medicinal products.
